



**Solid Research
Solid Relationships**

Fundamental Outlook

Market Setup

- **U.S. stocks** **were higher** after the close on Wednesday, as gains in the Technology, Industrials and Consumer Goods sectors led shares higher.
- **Dow Futures** is currently trading **137 pts down (-0.2%)**
- **Asian markets** are mostly trading **higher in the range of ~2%**
- Indian equities ended largely flat on Wednesday amid weak global cues and macro concerns. The Nifty 50 closed marginally higher by 0.2%, while broader markets remained subdued with the Midcap100 gaining 0.5% and the Smallcap100 ending nearly flat (+0.04%)
- **Gift nifty** is currently trading with **gains of 0.8%**
- **FII's: -1,597 Cr DII's: +1,968 Cr**

Opening Cues: Flat to Positive

Aditya Birla Capital has approved a preferential issue of 112.4m equity shares at a price of Rs 356.02/share aggregating upto Rs 40b through private placement, subject to shareholder and regulatory approvals.

View: **Positive**

Dr. Reddy's has launched its oral semi glutide biosimilar for type 2 diabetes mellitus in India, and it will be sold under the brand name Obeda.

View: **Positive**

JSW Energy to raise up Rs 4,000 crore via QIP, indicative issue price at Rs 525-527/ share. The raised capital is to support its ambitious growth roadmap, targeting 30 GW of installed power generation capacity by FY30.

View: **Positive**

Q4FY26 Results

Above Expectations: Samvardhana Motherson, Lenskart, Grasim, Apollo Hospitals

Below Expectations: Prince Pipes, Eris Lifesciences

Inline/Mixed: Astral, BEL, BPCL, Metro Brands, Bosch

Weak: Jubilant Food works

Fundamental Actionable Idea

Samvardhana Motherson

CMP INR132, TP: 160; Upside 21% View: Buy, MTF Stock

- Samvardhana Motherson delivered a strong 4QFY26 performance, with adj. PAT rising 55% YoY and EBITDA margin expanding 200bp to 11%, driven by robust execution and margin improvement across wiring harness, integrated assemblies, and emerging businesses.
- The company's growth visibility remains strong, supported by a USD96b booked business pipeline, multiple greenfield projects across global markets, upcoming acquisitions, and rapid scaling in high-growth segments such as consumer electronics and aerospace.
- Management has raised its five-year revenue aspiration to USD108b, while strong order backlog, EV transition, premiumization trends, and improving leverage position are expected to support sustained growth and earnings expansion over the medium term.
- Given the better-than-expected performance in 4Q despite adverse global macro, we raise our earnings estimates by 8% each for FY27/FY28.

View: BUY

Fundamental Actionable Idea

Grasim

CMP INR2,972, TP:3,440; Upside 16% View: Buy, MTF Stock

- Grasim Industries delivered a strong 4QFY26 performance, with EBITDA surging 2.5x YoY driven by robust execution across key segments, sharp margin expansion in the VSF business, and healthy growth in paints and B2B e-commerce.
- Birla Opus continued its rapid scale-up, crossing 10% market share in Mar'26, supported by an expanding dealer network of 50,000+ dealers across 11,500 towns, improving dealer throughput, and increasing premium product penetration.
- The company's multi-engine growth strategy remains intact, supported by strong momentum in paints, improving VSF realizations and margins, healthy chemical volumes, and scaling up of the Birla Pivot B2B building materials platform.
- We now model a CAGR of 25%/42%/44% in revenue/pre-IND AS EBITDA/PAT over FY26-28E, driven by ~26%/23% revenue growth and ~275bp/350bp margin expansion in India/International.

View: BUY

Velocity Idea

Zydus Lifesciences

RECO: BUY; CMP: ₹1,047; SL: ₹950(9%); TGT: ₹1,240(18%)

- Zydus reported a strong Q4FY26 performance, led by 14% growth in India formulations with continued outperformance across Cardiology, Respiratory, and Oncology. International formulations surged 40% YoY, while North America delivered resilient 10% constant-currency growth, supported by niche and specialty products.
- The launch of Tishta, the world's first Nivolumab biosimilar, alongside its first oncology 505(b)(2) product in the US, marks a strategic shift toward high-margin, differentiated businesses.
- Rising contribution from chronic therapies, med-tech expansion, and a diversified specialty-led portfolio strengthen long-term growth visibility. Additionally, the ₹1,100 Cr. buyback at ₹1,150 per share (14% premium) enhances near-term shareholder return visibility.
- The Stock has broken out from a falling supply trendline with higher than average traded volumes on the daily scale.
- The RSI momentum indicator is rising which confirms the positive price action.

India Pharma Pulse Basket

- India’s pharma industry is witnessing a structural shift toward high-value segments such as CDMO, biosimilars, GLP-1 therapies, and complex generics, supported by rising global outsourcing and China+1 opportunities.
- Rising demand for obesity and diabetes drugs such as semaglutide is creating a major growth opportunity for Indian pharma players, with multiple companies preparing launches and expanding peptide manufacturing capabilities.
- Strong policy support through initiatives such as the ₹10,000 crore “Biopharma Shakti” program and PLI schemes for APIs/KSMs is accelerating India’s ambition to become a global biopharma and advanced manufacturing hub.

Time Frame: 12 months

Review: Monthly

Upside: 10–15%

Risk: High

Benchmark: Nifty 200

Script	Market Cap (Rs Cr)	CMP as on 7 th May 2026	Weightage (%)
Lupin	1,11,826	2,460	20
Mankind Pharma	98,074	2,376	20
Glenmark Pharma	66,927	2,370	20
Laurus Labs	65,026	1,204	20
Granules India	18,440	743	20

Weightage Rationale: We have assigned equal weightage to all the stocks in the basket as we expect equal growth opportunity in each of them.

Result Estimate – 21st May, 2026

Name	Sales (INR Crores)	Growth (%)		EBIDTA (INR Crores)	Growth (%)		PAT (INR Crores)	Growth (%)	
	Mar-26	YoY	QoQ	Mar-26	YoY	QoQ	Mar-26	YoY	QoQ
Bikaji Foods	695	13%	-12%	99	34%	1%	63	58%	1%
Emami	945	-2%	-18%	206	-6%	-46%	155	-15%	-55%
Page Industries	1,194	9%	-14%	246	5%	-23%	166	1%	-23%
Happy Forgings	417	18%	7%	127	24%	5%	80	18%	1%
JSW Cement	1,844	8%	14%	305	22%	7%	45	7%	-65%
ITC	19,871	6%	-1%	6,806	4%	-1%	5,094	0%	-2%
LG Electronics	8,145	9%	98%	1,077	2%	417%	804	7%	593%
Life Insurance Corp.	1,60,460	9%	28%	4,423	25%	39%	19,288	1%	49%
Repco Home Fin	195	14%	-1%	140	7%	5%	118	3%	8%
Aurobindo Pharma	8,678	4%	0%	1,831	-2%	3%	1,012	7%	9%
Dr Agarwals Health.	550	19%	4%	150	13%	4%	36	0%	6%
Laxmi Dental	71	17%	8%	12	25%	71%	10	137%	104%
Max Healthcare	2,663	16%	8%	671	11%	6%	417	7%	3%
GAIL	32,556	-9%	-4%	2,194	-32%	-17%	1,039	-49%	-35%
Prestige Estates	2,820	84%	-27%	859	59%	0%	228	811%	2%
FSN E-Commerce	2,588	26%	-10%	205	54%	-10%	74	287%	-5%

Focus Investment Ideas

All Stocks Available in MTF

Duration : 1 Year Horizon

Stock Name	Rating	CMP (Rs)	Target (Rs)	Upside (%)
Waaree Energies	Buy	3005	3850	28%
Delhivery	Buy	457	570	25%
ICICI Prudential AMC	Buy	3137	3850	23%
Jindal Steel	Buy	1223	1450	19%
Fortis Healthcare	Buy	975	1100	13%

Technical Outlook

Nifty Technical Outlook

NIFTY (CMP : 23659) Nifty immediate support is at 23600 then 23400 zone while resistance at 24000 then 24200 zones. Now it has to hold above 23600 zones for an up move towards 24000 then 24200 zones while on the downside support can be seen at 23600 then 23400 zones.

4-Nifty50 - 20/05/26



Bank Nifty Technical Outlook

21-May-26

BANK NIFTY (CMP : 53562) Bank Nifty support is at 53250 then 53000 zones while resistance at 54000 then 54500 zones. Now it has to hold above 53500 zones for a bounce towards 54000 then 54500 levels while on the downside support is seen at 53250 then 53000 zones.

4-Niftybank - 20/05/26



Sensex Technical Outlook

21-May-26

Sensex (CMP : 75318) Sensex support is at 75000 then 74700 zones while resistance at 76000 then 76200 zones. Now it has to hold above 75000 zones for an up move towards 76000 then 76200 levels while support is placed at 75000 then 74700 zones.


4-S&P BSESENSX - 20/05/26



Investment in securities market are subject to market risks, read all the related documents carefully before investing.

Midcap100 Index Technical Outlook


- The Index is hovering around its 20 DEMA support zones.
- The market breadth was in favour of the advances.



Nifty Midcap100 Stats	
Advance	Decline
62	38

Smallcap250 Index Technical Outlook

- Bouncing up from previous swing lows.
- The market breadth was neutral.



Nifty SmallCap250 Stats

Advance

123

Decline

127

BRENT CRUDE



Sectoral Performance - Daily

- The Sectors closed on a mixed note.

	Closing	% Change							
Indices	20-May	1-day		2-days		3-days		5-days	
NIFTY 50	23659		0.17%		0.04%		0.07%		1.05%
NIFTY BANK	53562		0.29%		0.05%		-0.28%		0.20%
NIFTY MIDCAP 100	61323		0.49%		1.40%		1.25%		1.93%
NIFTY SMALLCAP 250	16678		0.08%		1.24%		-0.27%		-0.63%
NIFTY FINANCIAL SERVICES	25295		0.04%		-0.22%		-0.19%		0.71%
NIFTY PRIVATE BANK	26030		0.25%		-0.50%		-0.27%		0.68%
NIFTY PSU BANK	7971		0.43%		1.24%		-0.70%		-1.16%
NIFTY IT	29185		-0.42%		2.80%		5.30%		4.54%
NIFTY FMCG	50521		-0.71%		-0.75%		-1.04%		-0.17%
NIFTY OIL & GAS	11359		1.59%		1.76%		0.96%		-0.69%
NIFTY PHARMA	24843		-0.10%		0.32%		0.85%		3.96%
NIFTY AUTO	25914		0.84%		1.13%		-0.60%		0.10%
NIFTY METAL	13187		0.17%		0.13%		-0.86%		-0.78%
NIFTY REALTY	767		0.57%		2.01%		1.42%		0.37%
NIFTY INDIA DEFENCE	8991		0.79%		0.41%		-0.10%		-1.14%

Sectoral Performance - Weekly

- Among the weekly sectoral indices change relative strength was seen in Nifty Pharma.

Name	1W Change	2W Change	3W Change	4W Change	5W Change
Nifty 50	0.07	-2.14	-1.41	-1	-2.85
Nifty Bank	-0.28	-3.16	-2.37	-4.51	-5.31
Nifty IT	5.3	-0.71	-0.57	2.29	-8.25
Nifty Auto	-0.6	-4.94	-0.01	1.02	-1.97
Nifty Metal	-0.86	1.04	2.75	3.45	2.38
Nifty Pharma	0.85	3.04	6.77	10.02	10.43
Nifty FMCG	-1.04	-1.26	-1.08	-0.48	1.74
Nifty Realty	1.42	-6.87	-3.34	-1.41	-2.52
Nifty Media	-2.51	-4.94	-3.84	-2.69	-1.17
Nifty PSU Bank	-0.7	-4.79	-6.03	-9.54	-10.06



MANAPPURAM FINANCE

(Mcap ₹ 27,014 Cr.)

F&O Stock, MTF stock

- Range breakout on daily chart.
- Strong bodied bullish candle.
- Stock trading near life highs.
- RSI momentum indicator showing strength.
- We recommend to buy the stock at CMP ₹319 with a SL of ₹306 and a TGT of ₹352.

	RECOs	CMP	SL	TARGET	DURATION
	BUY	319	306	352	1 Week



Technical Stocks On Radar

NARAYAN HRUDAYALAYA

(CMP: 1902, Mcap ₹ 38,878 Cr.)

F&O Stock, MTF stock

- Range breakout on daily chart.
- Strong bullish candle.
- RSI indicator positively placed.
- Immediate support at 1840.



TIMKEN

(CMP: 3656, Mcap ₹ 27,501 Cr.)

MTF stock


- More momentum above 3740 .
- Noticeable volumes.
- RSI indicator bullish crossover.
- Immediate support at 3550.



Derivative Outlook

Nifty : Option Data

- Maximum Call OI is at 24000 then 24500 strike while Maximum Put OI is at 23500 then 23000 strike.
- Call writing is seen at 23500 then 23600 strike while Put writing is seen at 23500 then 23400 strike.
- Option data suggests a broader trading range in between 23200 to 24000 zones while an immediate range between 23400 to 23800 levels.



Option - Buying side strategy

Index	Single Leg Buying	Multi Leg Strategy
Nifty (Weekly)	23900 CE if it sustains above 23600 zones	Bull call spread (Buy 23900 CE and Sell 24000 CE) at net premium cost of 25-30 points
Sensex (Weekly)	75800 CE if it sustains above 75000 zones	Bull call spread (Buy 75800 CE and Sell 76000 CE) at net premium cost of 60-70 points
Bank Nifty (Monthly)	54500 CE if it sustains above 53500 zones	Bull call spread (Buy 54200 CE and Sell 54700 CE) at net premium cost of 220-230 points


Option - Selling side strategy

Index	Writing
Nifty (Monthly)	22700 PE and 24550 CE
Sensex (Weekly)	74200 PE and 76500 CE
Bank Nifty (Monthly)	52000 PE and 55700 CE


Weekly Option Range for Option Writers based on Different Confidence Band								
Date		21-May-26	Weekly Expiry		26-May-26	Days to weekly expiry		4
								
Nifty		23659	India VIX		18.4			
Confidence Band	Probability	% Away From Spot	Range				Total Premium (Put + Call)	Types of Trades
			Put	Premium	Call	Premium		
1.00	68%	± 1.7%	23250	61	24050	64	125	Aggressive
1.25	79%	± 2.2%	23150	46	24150	43	88	Less Aggressive
1.50	87%	± 2.6%	23050	35	24250	28	62	Neutral
1.75	92%	± 3.0%	22950	26	24350	18	44	Conservative
2.00	95%	± 3.4%	22850	20	24450	12	31	Most Conservative
Date		21-May-26	Monthly Expiry		26-May-26	Days to weekly expiry		4
Bank Nifty		53562						
Confidence Band	Probability	% Away From Spot	Range				Total Premium (Put + Call)	Types of Trades
			Put	Premium	Call	Premium		
1.00	68%	± 2.2%	52400	170	54800	182	352	Aggressive
1.25	79%	± 2.5%	52200	140	55000	142	282	Less Aggressive
1.50	87%	± 3.1%	51900	106	55300	99	204	Neutral
1.75	92%	± 3.7%	51600	76	55600	69	145	Conservative
2.00	95%	± 4.2%	51300	57	55900	48	105	Most Conservative
Investments in securities markets are subject to market risks. Please read all related documents carefully.								

Nifty Advance Decline & Ban update

Stocks in Ban: SAIL and KAYNES



Stocks : Derivatives Outlook



Stocks : Options on radar

Stock	Call Strike	Trade	Buying Range	SL	TGT	Logic
MANKIND	2600 CE	Buy	40-44	30	65	Long Buildup
CUMMINSIND	5400 CE	Buy	90-95	80	115	Long Buildup
OFSS	9730 CE	Buy	160-170	135	220	Long Buildup

Stock	Call Strike	Trade	Buying Range	SL	TGT	Logic
AMBER	7000 PE	Buy	100-110	80	150	Short Buildup
KAYNES	3000 PE	Buy	90-100	70	140	Long Liquidation

Quant Outlook

Quant Intraday Sell Ideas

What is this?

Based on technical indicators this strategy gives 2 stocks that have a high likelihood to fall during the day (from open to close). This is an intraday Sell strategy which can provide a good cushioning during a black swan event.

Today's **Sell** Ideas:

Stock Names	Close Price	SL (1%)	TP (1%)
IREDA (Sell)	126.95	128.22	125.68
HCLTECH (Sell)	1172.2	1183.92	1160.48

What are the rules?

- Stock names will be given at market open (9:15 am)
- Recommended time to entry: between 9:15 to 9:30 am.
- Entry: We short 2 stocks daily (intraday)
- Exit: we will exit at 3:15 as this is an intraday call
- SL: is placed at 1% of the open.
- Book profit: At 1% fall since open.
- In special situations the book profit might be delayed if the stock is in free fall.

Siddhartha Khemka
Head – Retail Research

Chandan Taparia, CMT, CFTe
Head – Derivatives & Technical Research

Ruchit Jain
Head – Technical Research

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

MOFSL, its associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report..

In the past 12 months, MOFSL or any of its associates may have:

- a) received any compensation/other benefits from the subject company of this report
- b) managed or co-managed public offering of securities from subject company of this research report,
- c) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- d) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

- MOFSL and its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.

(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients.

Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement

Analyst ownership of the stock	No
--------------------------------	----

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) “SFO”. As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to “Professional Investors” as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors.” Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. (“MOCMSPL”) (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as “institutional investors” as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore (“SFA”) or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an “institutional investor” nor an “accredited investor”, they must immediately discontinue any use of this Report and inform MOCMSPL . In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani
Email: nainesh.rajani@motilaloswal.com
Contact: (+65) 8328 0276

Disclaimer:

This report is intended for distribution to Retail Investors.

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN.: 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.